[Clinical and biological study of a new vascular protective agent and hypolipemic agent, pyridoxine para-chloro-phénoxy-isobutyrate. (Claresan)].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Y Mouton.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Plasma concentrations of soluble receptors for tumor necrosis factor type II (sTNFRII) and CD4+ lymphocyte counts were determined in patients with HIV-1 infection grouped according to the 1993 classification of the CDC. Compared with healthy controls (mean +/- SD = 2.83 +/- 0.70 ng/ml; n = 20), higher values of sTNFRII were obtained in most of patients of all groups of HIV-1-infected patients. The levels of sTNFRII were 5.29 +/- 1.75 ng/ml (n = 23) for stage A1 patients, 5.27 +/- 2.25 ng/ml (n = 37) for stage A2 patients, 6.03 +/- 1.9 ng/ml (n = 14) for stage A3 patients, 7.41 +/- 3.25 ng/ml (n = 21) for stage B and stage C patients. Intra-individual variance in sTNFRII levels in eight clinically stable patients with HIV-1 infection was observed in the course of a short-time follow-up. The increase of sTNFRII plasma levels in five out of ten patients was shown at time lapses of 3 years. In contrast to previous reports no inverse correlation between sTNFRII and CD4+ lymphocyte counts was found in all stages of disease. The increased level of sTNFRII in circulating blood might reflect the activation of the TNF alpha system. These results support an activation of this system occurring early in the course of HIV infection.
Explore the source record for details and available documents.
Although measles vaccine has been licensed since 1968, immunization against measles has not met with much success in France, partly because the disease is no longer feared. The level of vaccination coverage appears to be less than 20%. Indeed, the present epidemiologic situation is similar to the natural situation in a developed country. A multicenter, retrospective hospital survey revealed that 1,157 patients with measles were hospitalized during a 30-month period in five areas (total population, 4.2 million). Analysis of the preliminary results of this survey and of available national data showed an incidence of 5.6-7.5 cases per 1,000 population; a hospitalization rate of one per 10,000; a death rate of 0.56 per 1 million; and a disability rate of 0.48 per 1 million. Encephalitis (the definition of which should be reappraised) occurred once in 2,850 cases, and subacute sclerosing panencephalitis was not rare (incidence, one case per 2.6 million people). The problem posed by measles is sufficiently grave to justify a national campaign urging the widespread vaccination of children.
Explore the source record for details and available documents.